Vaxart (OTCMKTS:VXRT) Shares Cross Below Two Hundred Day Moving Average – What’s Next?

Vaxart, Inc. (OTCMKTS:VXRT) shares crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $0.58 and traded as low as $0.4315. Vaxart shares last traded at $0.4345, with a volume of 267,426 shares traded.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised Vaxart to a “hold” rating in a report on Thursday, July 9th. One equities research analyst has rated the stock with a Hold rating. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Vaxart Stock Performance

The firm’s 50 day simple moving average is $0.50 and its 200 day simple moving average is $0.58. The firm has a market capitalization of $105.86 million, a price-to-earnings ratio of 2.72 and a beta of 1.05.

Vaxart (OTCMKTS:VXRT) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.06. Vaxart had a net margin of 15.88% and a return on equity of 53.04%. The firm had revenue of $27.18 million for the quarter, compared to analyst estimates of $26.21 million. As a group, sell-side analysts forecast that Vaxart, Inc. will post -0.68 earnings per share for the current year.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company focused on developing oral recombinant vaccines. Unlike conventional injectable vaccines, Vaxart’s vaccine candidates are designed to be administered as tablets, with the goal of stimulating both systemic and mucosal immune responses.

The company’s research programs have focused on infectious diseases including coronavirus infections, influenza and norovirus. Vaxart has developed vaccine candidates using its oral vaccine platform and has evaluated them in clinical studies, but the company does not have a marketed vaccine product.

Vaxart is based in the United States and conducts its research and clinical development activities primarily through U.S.-based operations and collaborations.